Start your subscription today to begin treatment with EndeavorOTC, the game-based ADHD treatment clinically designed to improve symptoms, attention and focus, designed with the same technology as the world’s first FDA-authorized game-based treatment. The treatment includes Focus Score, a first-of-its-kind personalized metric where you can track attention progress. EndeavorOTC is for adults 18 years and older with ADHD experiencing inattention-related challenges that affect their quality of life such as diminished focus, inability to complete projects or tasks, keep track of important items, and more. Built with the same technology as EndeavorRx, the world's first FDA-authorized video game treatment. EndeavorOTC is available now by subscription. No prescription needed. EndeavorOTC was studied in more than 220 participants over a 6-week period. In the clinical trial, 88% of participants saw improvement in their attention and 73% of participants reported quality of life improvements, including an increased ability to balance projects, get things done on time and keep track of important items like phone, wallet, and keys. There were no lasting or serious side effects in any clinical trials for EndeavorOTC. (1,2) How EndeavorOTC improves focus: The gameplay challenges you to tap targets and navigate obstacles to boost your attention and focus. As you progress through the game, the technology is continuously measuring your performance and using adaptive algorithms to adjust the difficulty and personalize the treatment experience. How to Play EndeavorOTC: Playing EndeavorOTC can fit into your daily routine. The more you play, the better your results. Playing the game every day for an initial six weeks can improve your attention and other functions that make up your ability to focus. Users will be given a target Focus Score increase which should be achievable in six weeks. Based on clinical trial data, the target increase provided directly relates to improvement in ADHD-related symptoms and overall quality of life. And, for the vast majority of people, this will leave room for continued improvement in Focus Score and cognitive abilities as well as ADHD symptom management beyond the initial six week course of treatment. EndeavorOTC is made available under the U.S. Food and Drug Administration’s (FDA) current Enforcement Policy for Digital Health Devices for Treating Psychiatric Disorders During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. EndeavorOTC has not been cleared or authorized by the FDA for its indications. It is recommended that patients speak to their health care provider before starting EndeavorOTC treatment, and before making any medical decisions. © 2024 Akili Interactive Labs, Inc. All Rights Reserved. Akili, EndeavorRx, Endeavor, Akili Care, ADHD Insight, Insight, EndeavorRx Insight, EndeavorOTC, SSME, and Akili Assist, as well as the logos for each, are trademarks or registered trademarks of Akili Interactive Labs, Inc. Other trademarks are trademarks or registered trademarks of their respective owners. For full instructions for use, please visit https://www.endeavorotc.com/IFU/. For more information, visit EndeavorOTC.com. Questions? Email Support@EndeavorOTC.com Terms of Use: https://my.akili.care/terms Privacy Notice: https://www.akiliinteractive.com/privacy-notice 1 Stamatis, C. A., Mercaldi, C., & Kollins, S. H., J Am Acad Child Adolesc Psychiatry, 62, S318 (2023). As measured by average percent change in the Test of Variables of Attention-Attention Comparison Score (TOVA-ACS). 2 As measured by the validated Adult ADHD Quality of Life Scale (AAQoL)
